[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628072":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":32,"responsibleParty":49,"collaborators":30,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":30,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":30,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":30,"overallStatus":34,"whyStopped":30,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"FET-PET\u002FMRI","EXPERIMENTAL","Patients who desire surgery and have active Cushing's Disease, Acromegaly, or tumoral hyperprolactinemia, occult tumor on DCE-MRI",[13],"Drug: FET-PET\u002FMRI",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients will undergo PET\u002FMR scan after intravenous administration of 5 mCi ± 0.5 mCi of Fluoroethyl-L-tyrosine (\\[18F\\]FET)",[9],[20],"Fluoroethyl-L-tyrosine",[22],{"name":23,"affiliation":5,"role":24},"Neetu Soni, MBBS, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Julia Santos","CONTACT","904-953-3280",null,"santos.julia@mayo.edu",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Jacksonville","Florida","32224","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-81.65565,30.33218,{"lat":44,"lon":43},[47,48],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":30},{"name":23,"role":24,"phone":30,"phoneExt":30,"email":30},{"type":24,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Neetu Soni","Principal Investigator","100628072","phase-1-use-of-18f-fluoroethyl-l-tyrosine-petmri-for-identifying-small-functional-pituitary-adenomas-100628072",false,"NCT07456878","Use of [18F] Fluoroethyl-L-tyrosine PET\u002FMRI for Identifying Small Functional Pituitary Adenomas","Inclusion Criteria:\n\n* Patients 18 to 75 years of age with biochemically proven CD, Acromegaly, or tumor hyperprolactinemia as per current Endocrinology guidelines.\n* Clinical DCE-MRI protocol that is negative or equivocal for identifiable tumor.\n* Patient willing to have surgery if lesion found, or already scheduled for surgery and lesion identification would be helpful.\n* Able to provide informed consent and be capable of completing the imaging protocols.\n* Female subjects of childbearing potential (women of childbearing potential \\[WOCBP\\]) must have a negative urine pregnancy test ≤48 hours prior to the 18F-FET injection.\n\nExclusion Criteria:\n\n* Patients with contraindications to MRI or PET scans.\n* Patients with known allergies to contrast agents or other imaging-related materials.\n* Patients with severe medical conditions that preclude participation in the study (e.g. inability to lie supine for 30-60 minutes).\n* Patients with successful MRI localization of the adenoma.","ALL","18 Years","75 Years",{"count":62,"type":63},5,"ESTIMATED","INTERVENTIONAL",[66],"PHASE1","The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET\u002FMRI in detecting MRI-occult primary or residual\u002Frecurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.",[69],"Pituitary Adenoma","2026-03-03",{"date":72,"type":73},"2026-03-09","ACTUAL",{"date":75,"type":73},"2026-01-08",{"date":77,"type":63},"2026-12",{"name":5,"class":6},1]